145 related articles for article (PubMed ID: 15528325)
21. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.
Lugade AA; Moran JP; Gerber SA; Rose RC; Frelinger JG; Lord EM
J Immunol; 2005 Jun; 174(12):7516-23. PubMed ID: 15944250
[TBL] [Abstract][Full Text] [Related]
22. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
Valmori D; Fonteneau JF; Lizana CM; Gervois N; Liénard D; Rimoldi D; Jongeneel V; Jotereau F; Cerottini JC; Romero P
J Immunol; 1998 Feb; 160(4):1750-8. PubMed ID: 9469433
[TBL] [Abstract][Full Text] [Related]
23. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; Onoé K
J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
[TBL] [Abstract][Full Text] [Related]
25. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.
Matsui S; Ahlers JD; Vortmeyer AO; Terabe M; Tsukui T; Carbone DP; Liotta LA; Berzofsky JA
J Immunol; 1999 Jul; 163(1):184-93. PubMed ID: 10384115
[TBL] [Abstract][Full Text] [Related]
26. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles.
Storni T; Lechner F; Erdmann I; Bächi T; Jegerlehner A; Dumrese T; Kündig TM; Ruedl C; Bachmann MF
J Immunol; 2002 Mar; 168(6):2880-6. PubMed ID: 11884458
[TBL] [Abstract][Full Text] [Related]
27. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity.
Dorothée G; Vergnon I; Menez J; Echchakir H; Grunenwald D; Kubin M; Chouaib S; Mami-Chouaib F
J Immunol; 2002 Jul; 169(2):809-17. PubMed ID: 12097384
[TBL] [Abstract][Full Text] [Related]
28. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
Rice J; Buchan S; Stevenson FK
J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
[TBL] [Abstract][Full Text] [Related]
29. CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.
Puliaev R; Puliaeva I; Welniak LA; Ryan AE; Haas M; Murphy WJ; Via CS
J Immunol; 2008 Jul; 181(1):47-61. PubMed ID: 18566369
[TBL] [Abstract][Full Text] [Related]
30. On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen.
Bai XF; Gao JX; Liu J; Wen J; Zheng P; Liu Y
Cancer Res; 2001 Sep; 61(18):6860-7. PubMed ID: 11559562
[TBL] [Abstract][Full Text] [Related]
31. CD4+ T cells can protect APC from CTL-mediated elimination.
Mueller SN; Jones CM; Stock AT; Suter M; Heath WR; Carbone FR
J Immunol; 2006 Jun; 176(12):7379-84. PubMed ID: 16751382
[TBL] [Abstract][Full Text] [Related]
32. Lipopolysaccharide modulation of dendritic cells is insufficient to mature dendritic cells to generate CTLs from naive polyclonal CD8+ T cells in vitro, whereas CD40 ligation is essential.
Kelleher M; Beverley PC
J Immunol; 2001 Dec; 167(11):6247-55. PubMed ID: 11714787
[TBL] [Abstract][Full Text] [Related]
33. Functional dichotomy in CD40 reciprocally regulates effector T cell functions.
Murugaiyan G; Agrawal R; Mishra GC; Mitra D; Saha B
J Immunol; 2006 Nov; 177(10):6642-9. PubMed ID: 17082576
[TBL] [Abstract][Full Text] [Related]
34. Human CD5 protects circulating tumor antigen-specific CTL from tumor-mediated activation-induced cell death.
Friedlein G; El Hage F; Vergnon I; Richon C; Saulnier P; Lécluse Y; Caignard A; Boumsell L; Bismuth G; Chouaib S; Mami-Chouaib F
J Immunol; 2007 Jun; 178(11):6821-7. PubMed ID: 17513730
[TBL] [Abstract][Full Text] [Related]
35. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody.
Tutt AL; O'Brien L; Hussain A; Crowther GR; French RR; Glennie MJ
J Immunol; 2002 Mar; 168(6):2720-8. PubMed ID: 11884438
[TBL] [Abstract][Full Text] [Related]
36. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance.
Nguyen LT; Elford AR; Murakami K; Garza KM; Schoenberger SP; Odermatt B; Speiser DE; Ohashi PS
J Exp Med; 2002 Feb; 195(4):423-35. PubMed ID: 11854356
[TBL] [Abstract][Full Text] [Related]
37. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors.
Plautz GE; Mukai S; Cohen PA; Shu S
J Immunol; 2000 Oct; 165(7):3656-62. PubMed ID: 11034369
[TBL] [Abstract][Full Text] [Related]
38. Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area.
Rosato A; Zambon A; Macino B; Mandruzzato S; Bronte V; Milan G; Zanovello P; Collavo D
Int J Cancer; 1996 Mar; 65(6):847-51. PubMed ID: 8631602
[TBL] [Abstract][Full Text] [Related]
39. The cross-priming APC requires a Rel-dependent signal to induce CTL.
Mintern JD; Belz G; Gerondakis S; Carbone FR; Heath WR
J Immunol; 2002 Apr; 168(7):3283-7. PubMed ID: 11907083
[TBL] [Abstract][Full Text] [Related]
40. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response.
Gri G; Gallo E; Di Carlo E; Musiani P; Colombo MP
J Immunol; 2003 Jan; 170(1):99-106. PubMed ID: 12496388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
